STI

STI Pharma is a privately held U.S. specialty pharmaceutical company focused on the acquisition, development, licensing, and commercialization of generic prescription drugs. The company appears to concentrate on niche and hospital-oriented products, particularly injectable formulations, while also maintaining capabilities in oral solids, topical products, and liquids. Its commercial portfolio includes generic oncology and acute-care injectables such as carmustine, arsenic trioxide, thiotepa, succinylcholine, and isoproterenol hydrochloride. STI Pharma also states that it operates an internal formulation and analytical development laboratory and works with U.S. FDA-approved contract manufacturing partners to supply products to the U.S. market. Overall, the business is best characterized as a small specialty generics company with internal R&D, outsourced manufacturing, and a growing injectable pipeline.